Literature DB >> 2223847

Conditions affecting the activity of glucocerebrosidase purified from spleens of control subjects and patients with type 1 Gaucher disease.

J M Aerts1, M C Sa Miranda, E M Brouwer-Kelder, S Van Weely, J A Barranger, J M Tager.   

Abstract

Glucocerebrosidase was purified to homogeneity from spleens of control subjects and Type 1 Gaucher disease patients by immunoaffinity chromatography. Activation of the enzyme by taurocholate, phosphatidylserine and sphingolipid activator protein 2 (saposin C; SAP-2) was investigated by titration of combinations of various effectors in the absence and presence of Triton X-100. The specific activity of Type 1 Gaucher glucocerebrosidase was found to be less than 20% of the corresponding control value under most conditions. However, in the presence of optimal amounts of activator protein SAP-2 and phosphatidylserine (and in the absence of Triton X-100 and/or taurocholate), the specific activity of mutant enzyme towards artificial and natural lipid substrates was close to normal when measured at pH 5.0-5.5. At pH values below 5.0, the specific activity of mutant enzyme decreased more rapidly compared to that of control enzyme. The activity of Type 1 Gaucher glucocerebrosidase in the intact cell might, in a comparable manner, be highly dependent on the extent of activation by endogenous activators and on the intralysosomal pH. Values for residual glucocerebrosidase activity, as measured in vitro in extracts of cells and tissues from Type 1 Gaucher disease patients, are indeed highly dependent on the assay conditions employed. Consequently such measurements are of little value in the assessment of the actual capacity for glucosylceramide hydrolysis and for prediction of the clinical severity of the disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2223847     DOI: 10.1016/0167-4838(90)90122-v

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Molecular imaging of membrane interfaces reveals mode of beta-glucosidase activation by saposin C.

Authors:  Jean-René Alattia; James E Shaw; Christopher M Yip; Gilbert G Privé
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-22       Impact factor: 11.205

2.  Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease.

Authors:  S van Weely; M van den Berg; J A Barranger; M C Sa Miranda; J M Tager; J M Aerts
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

Review 3.  Pathogenesis of lysosomal storage disorders as illustrated by Gaucher disease.

Authors:  J M Aerts; S Van Weely; R Boot; C E Hollak; J M Tager
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

4.  The N370S (Asn370-->Ser) mutation affects the capacity of glucosylceramidase to interact with anionic phospholipid-containing membranes and saposin C.

Authors:  Rosa Salvioli; Massimo Tatti; Susanna Scarpa; Sabrina Maria Moavero; Fiorella Ciaffoni; Federica Felicetti; Christine R Kaneski; Roscoe O Brady; Anna Maria Vaccaro
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

Review 5.  The role of saposin C in Gaucher disease.

Authors:  Rafael J Tamargo; Arash Velayati; Ehud Goldin; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2012-05-05       Impact factor: 4.797

Review 6.  Alglucerase. A review of its therapeutic use in Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

Review 7.  Current methods to analyze lysosome morphology, positioning, motility and function.

Authors:  Duarte C Barral; Leopoldo Staiano; Cláudia Guimas Almeida; Dan F Cutler; Emily R Eden; Clare E Futter; Antony Galione; André R A Marques; Diego Luis Medina; Gennaro Napolitano; Carmine Settembre; Otília V Vieira; Johannes M F G Aerts; Peace Atakpa-Adaji; Gemma Bruno; Antonella Capuozzo; Elvira De Leonibus; Chiara Di Malta; Cristina Escrevente; Alessandra Esposito; Paolo Grumati; Michael J Hall; Rita O Teodoro; Susana S Lopes; J Paul Luzio; Jlenia Monfregola; Sandro Montefusco; Frances M Platt; Roman Polishchuck; Maria De Risi; Irene Sambri; Chiara Soldati; Miguel C Seabra
Journal:  Traffic       Date:  2022-04-24       Impact factor: 6.144

8.  Identification of novel splice site mutation IVS9 + 1(G > A) and novel complex allele G355R/R359X in Type 1 Gaucher patients heterozygous for mutation N370S.

Authors:  Kourtnee Hoitsema; Dominick Amato; Aneal Khan; Sandra Sirrs; Francis Y M Choy
Journal:  Meta Gene       Date:  2016-03-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.